Clinical investigator conflicts of interest
This article was originally published in The Gray Sheet
Executive Summary
FDA requests public comment Aug. 25 on its plan to require sponsors of device, drug or biologic applications to certify that their clinical investigators have no financial interests in the product's approval - or, alternatively, to disclose any interests and explain steps taken to minimize bias. The agency estimates additional reporting costs to the sponsor at less than $450,000...